Modeling excess zeroes in an integrated analysis of vaccine safety

In prophylactic vaccine studies in healthy populations, many subjects do not experience a single adverse event (AE). Thus, the number of AEs observed in such clinical trials may be difficult to model because of an excess of zeroes relative to the parametric distributions assumed. To determine which...

Full description

Saved in:
Bibliographic Details
Published inHuman vaccines & immunotherapeutics Vol. 14; no. 6; pp. 1530 - 1533
Main Authors Maansson, Roger, Radley, David, Jiang, Qin, Beeslaar, Johannes, Patterson, Scott, Absalon, Judith, Perez, John
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 03.06.2018
Taylor & Francis Group
Subjects
Online AccessGet full text
ISSN2164-5515
2164-554X
2164-554X
DOI10.1080/21645515.2018.1433972

Cover

Loading…
Abstract In prophylactic vaccine studies in healthy populations, many subjects do not experience a single adverse event (AE). Thus, the number of AEs observed in such clinical trials may be difficult to model because of an excess of zeroes relative to the parametric distributions assumed. To determine which type of modeling provides a better fit for observed AE data, a variety of models were applied to data from an integrated safety database from clinical trials of the meningococcal vaccine MenB-FHbp (Trumenba®, bivalent rLP2086; Pfizer Inc, Philadelphia, PA). MenB-FHbp was the first vaccine approved in the United States to prevent meningococcal serogroup B disease in individuals aged 10 to 25 years. Specifically, this report presents an integrated analysis of AEs from 8 randomized controlled trials that compared MenB-FHbp to placebo or active controls. The number of AEs occurring from dose one to 30 days after the last dose was analyzed. Six models were compared: standard Poisson and negative binomial models and their corresponding zero-inflation and hurdle models. Models were evaluated for their ability to predict the number of AEs and by goodness-of-fit statistics. Models based on the Poisson distribution were a poor fit. The zero-inflated negative binomial model and negative binomial hurdle model provided the closest fit. These results suggest that zero-inflated or hurdle models may provide a better fit to AE data from healthy populations compared with conventional parametric models.
AbstractList In prophylactic vaccine studies in healthy populations, many subjects do not experience a single adverse event (AE). Thus, the number of AEs observed in such clinical trials may be difficult to model because of an excess of zeroes relative to the parametric distributions assumed. To determine which type of modeling provides a better fit for observed AE data, a variety of models were applied to data from an integrated safety database from clinical trials of the meningococcal vaccine MenB-FHbp (Trumenba®, bivalent rLP2086; Pfizer Inc, Philadelphia, PA). MenB-FHbp was the first vaccine approved in the United States to prevent meningococcal serogroup B disease in individuals aged 10 to 25 years. Specifically, this report presents an integrated analysis of AEs from 8 randomized controlled trials that compared MenB-FHbp to placebo or active controls. The number of AEs occurring from dose one to 30 days after the last dose was analyzed. Six models were compared: standard Poisson and negative binomial models and their corresponding zero-inflation and hurdle models. Models were evaluated for their ability to predict the number of AEs and by goodness-of-fit statistics. Models based on the Poisson distribution were a poor fit. The zero-inflated negative binomial model and negative binomial hurdle model provided the closest fit. These results suggest that zero-inflated or hurdle models may provide a better fit to AE data from healthy populations compared with conventional parametric models.
In prophylactic vaccine studies in healthy populations, many subjects do not experience a single adverse event (AE). Thus, the number of AEs observed in such clinical trials may be difficult to model because of an excess of zeroes relative to the parametric distributions assumed. To determine which type of modeling provides a better fit for observed AE data, a variety of models were applied to data from an integrated safety database from clinical trials of the meningococcal vaccine MenB-FHbp (Trumenba®, bivalent rLP2086; Pfizer Inc, Philadelphia, PA). MenB-FHbp was the first vaccine approved in the United States to prevent meningococcal serogroup B disease in individuals aged 10 to 25 years. Specifically, this report presents an integrated analysis of AEs from 8 randomized controlled trials that compared MenB-FHbp to placebo or active controls. The number of AEs occurring from dose one to 30 days after the last dose was analyzed. Six models were compared: standard Poisson and negative binomial models and their corresponding zero-inflation and hurdle models. Models were evaluated for their ability to predict the number of AEs and by goodness-of-fit statistics. Models based on the Poisson distribution were a poor fit. The zero-inflated negative binomial model and negative binomial hurdle model provided the closest fit. These results suggest that zero-inflated or hurdle models may provide a better fit to AE data from healthy populations compared with conventional parametric models.In prophylactic vaccine studies in healthy populations, many subjects do not experience a single adverse event (AE). Thus, the number of AEs observed in such clinical trials may be difficult to model because of an excess of zeroes relative to the parametric distributions assumed. To determine which type of modeling provides a better fit for observed AE data, a variety of models were applied to data from an integrated safety database from clinical trials of the meningococcal vaccine MenB-FHbp (Trumenba®, bivalent rLP2086; Pfizer Inc, Philadelphia, PA). MenB-FHbp was the first vaccine approved in the United States to prevent meningococcal serogroup B disease in individuals aged 10 to 25 years. Specifically, this report presents an integrated analysis of AEs from 8 randomized controlled trials that compared MenB-FHbp to placebo or active controls. The number of AEs occurring from dose one to 30 days after the last dose was analyzed. Six models were compared: standard Poisson and negative binomial models and their corresponding zero-inflation and hurdle models. Models were evaluated for their ability to predict the number of AEs and by goodness-of-fit statistics. Models based on the Poisson distribution were a poor fit. The zero-inflated negative binomial model and negative binomial hurdle model provided the closest fit. These results suggest that zero-inflated or hurdle models may provide a better fit to AE data from healthy populations compared with conventional parametric models.
Author Beeslaar, Johannes
Absalon, Judith
Perez, John
Radley, David
Patterson, Scott
Maansson, Roger
Jiang, Qin
Author_xml – sequence: 1
  givenname: Roger
  surname: Maansson
  fullname: Maansson, Roger
  organization: Pfizer Vaccine Clinical Research and Development, Collegeville, PA, USA
– sequence: 2
  givenname: David
  surname: Radley
  fullname: Radley, David
  organization: Pfizer Vaccine Research and Development, Pearl River, NY, USA
– sequence: 3
  givenname: Qin
  surname: Jiang
  fullname: Jiang, Qin
  organization: Pfizer Innovative Health, Collegeville, PA, USA
– sequence: 4
  givenname: Johannes
  surname: Beeslaar
  fullname: Beeslaar, Johannes
  organization: Pfizer Vaccine Clinical Research and Development, Hurley, UK
– sequence: 5
  givenname: Scott
  surname: Patterson
  fullname: Patterson, Scott
  organization: Statistical Innovation, Sanofi Pasteur, Swiftwater, PA, USA
– sequence: 6
  givenname: Judith
  surname: Absalon
  fullname: Absalon, Judith
  organization: Pfizer Vaccine Research and Development, Pearl River, NY, USA
– sequence: 7
  givenname: John
  surname: Perez
  fullname: Perez, John
  organization: Pfizer Vaccine Clinical Research and Development, Collegeville, PA, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29393713$$D View this record in MEDLINE/PubMed
BookMark eNqFkU1vEzEQhi1UREvoTwDtkUuCvf5aCwmJVnxUKuICEjdr1jsbXG3sYjsV4dfjJWlEueCDPR4_887I71NyEmJAQp4zumK0o69apoSUTK5ayroVE5wb3T4iZ3N-KaX4dnKMmTwl5znf0Lo0bYVST8hpa7jhmvEzcvEpDjj5sG7wp8Ocm1-YIubGhwZC3QuuExQc6g2mXfa5iWNzB875gE2GEcvuGXk8wpTx_HAuyNf3775cflxef_5wdfn2eumE1mVpTIe9xo7LlnVC8UGOkrEWuOMOpQTsFdMdgGGmNxT7tlNc9DODHFSlFuRqrztEuLG3yW8g7WwEb_8kYlpbSMW7Ca0DNQoKzHRGi0Gg0UZx1G5oNZNczlpv9lq3236Dg8NQEkwPRB--BP_druOdVZRrUadfkJcHgRR_bDEXu_HZ4TRBwLjNlpn6xaaaJSr64u9exyb3JlRA7gGXYs4JxyPCqJ39tvd-29lve_C71r3-p875AsXHeWQ__af6N0IirjA
CitedBy_id crossref_primary_10_1002_sim_9575
Cites_doi 10.1080/10543400600719384
10.2307/1912557
ContentType Journal Article
Copyright 2018 Pfizer, Inc. 2018 Pfizer, Inc.
Copyright_xml – notice: 2018 Pfizer, Inc. 2018 Pfizer, Inc.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1080/21645515.2018.1433972
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
DocumentTitleAlternate R. MAANSSON ET AL
EISSN 2164-554X
EndPage 1533
ExternalDocumentID oai_doaj_org_article_ca6f40a198974d4e97963e7cd271535c
PMC6037446
29393713
10_1080_21645515_2018_1433972
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: ;
GroupedDBID ---
00X
0YH
30N
4.4
53G
AALUX
AAYXX
ABEIZ
ABUPF
ACGFS
ADBBV
ADCVX
AECIN
AENEX
AGYJP
AIJEM
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AOIJS
ARJSQ
BABNJ
BAWUL
BLEHA
BOHLJ
CCCUG
CITATION
DGEBU
DIK
EBS
EJD
H13
HYE
IPNFZ
KYCEM
M4Z
O9-
RIG
RPM
TDBHL
TFL
TFW
TTHFI
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
GROUPED_DOAJ
ID FETCH-LOGICAL-c477t-998eb7e835218463d5f5112a3c3ce55aeb6178aa919b90eb28634bf511e3a63c3
IEDL.DBID DOA
ISSN 2164-5515
2164-554X
IngestDate Wed Aug 27 01:30:36 EDT 2025
Thu Aug 21 18:33:01 EDT 2025
Fri Jul 11 10:33:03 EDT 2025
Thu Apr 03 07:08:39 EDT 2025
Thu Apr 24 22:57:11 EDT 2025
Tue Jul 01 02:46:05 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords hurdle models
Poisson
excess zeroes
zero-inflated models
negative binomial
vaccine adverse events
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c477t-998eb7e835218463d5f5112a3c3ce55aeb6178aa919b90eb28634bf511e3a63c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Area of expertise: statistical modelling, mathematical modelling.
OpenAccessLink https://doaj.org/article/ca6f40a198974d4e97963e7cd271535c
PMID 29393713
PQID 1993991084
PQPubID 23479
PageCount 4
ParticipantIDs doaj_primary_oai_doaj_org_article_ca6f40a198974d4e97963e7cd271535c
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6037446
proquest_miscellaneous_1993991084
pubmed_primary_29393713
crossref_primary_10_1080_21645515_2018_1433972
crossref_citationtrail_10_1080_21645515_2018_1433972
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-06-03
PublicationDateYYYYMMDD 2018-06-03
PublicationDate_xml – month: 06
  year: 2018
  text: 2018-06-03
  day: 03
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Human vaccines & immunotherapeutics
PublicationTitleAlternate Hum Vaccin Immunother
PublicationYear 2018
Publisher Taylor & Francis
Taylor & Francis Group
Publisher_xml – name: Taylor & Francis
– name: Taylor & Francis Group
References cit0001
Akaike H (cit0012) 1973
TRUMENBA (meningococcal group B vaccine) (cit0002) 2014
cit0015
References_xml – start-page: 267
  volume-title: In:
  year: 1973
  ident: cit0012
– volume-title: Full Prescribing Information
  year: 2014
  ident: cit0002
– ident: cit0001
  doi: 10.1080/10543400600719384
– ident: cit0015
  doi: 10.2307/1912557
SSID ssj0000702466
Score 2.1132727
Snippet In prophylactic vaccine studies in healthy populations, many subjects do not experience a single adverse event (AE). Thus, the number of AEs observed in such...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1530
SubjectTerms Adolescent
Adult
Biostatistics - methods
Child
Drug-Related Side Effects and Adverse Reactions - epidemiology
excess zeroes
Female
Humans
hurdle models
Male
Meningococcal Vaccines - administration & dosage
Meningococcal Vaccines - adverse effects
negative binomial
poisson
Randomized Controlled Trials as Topic
Short Report
vaccine adverse events
Young Adult
zero-inflated models
Title Modeling excess zeroes in an integrated analysis of vaccine safety
URI https://www.ncbi.nlm.nih.gov/pubmed/29393713
https://www.proquest.com/docview/1993991084
https://pubmed.ncbi.nlm.nih.gov/PMC6037446
https://doaj.org/article/ca6f40a198974d4e97963e7cd271535c
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEB5UELyIb-uLCF6r3SZNtkcVRTx4UvBWknSCgnTF3RX11zuTdpddEbx4bDqhYWaa-YZMvgE4KU3GYdymJlc6VZi51KF2qbc9a4o8-NrHaos7ffOgbh-Lx5lWX1wT1tIDt4o781YHlVku7TGqVlgachk0vs4N_ayF592XYt5MMhX3YEOxJx5U5pQPpAQLisn1nX52xmM8xJVdfdorJAXlfC4wRf7-30Dnz9rJmWB0vQarHYoU5-3q12EBmw1YbvtKfm7CBXc443vmAj_4GoD4wrcBDsVzI2wjpgwRNT21lCRiEMS79XzILoY24OhzCx6ur-4vb9KuWULqlTGjlNImdAYZUFHSpmVdhGgE6aXHorDo-DKgtWWvdGVG-XRfS-VYBqXVJLUNS82gwV0QlEHQPJIl-KdcWVtfhtoW6FUIWdB5Amqiqcp3TOLc0OKl6nWEoxMFV6zgqlNwAqfTaa8tlcZfEy7YDFNhZsKOA-QfVecf1V_-kcDxxIgV_Tl8HGIbHIyHFZcuEjrO-iqBndao008RCGKiQJmAmTP33Frm3zTPT5GdWzOjj9J7_7H4fVhhhcTSNHkAS6O3MR4SCBq5I1iU2d1R9PpvLdr-oA
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Modeling+excess+zeroes+in+an+integrated+analysis+of+vaccine+safety&rft.jtitle=Human+vaccines+%26+immunotherapeutics&rft.au=Roger+Maansson&rft.au=David+Radley&rft.au=Qin+Jiang&rft.au=Johannes+Beeslaar&rft.date=2018-06-03&rft.pub=Taylor+%26+Francis+Group&rft.issn=2164-5515&rft.eissn=2164-554X&rft.volume=14&rft.issue=6&rft.spage=1530&rft.epage=1533&rft_id=info:doi/10.1080%2F21645515.2018.1433972&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_ca6f40a198974d4e97963e7cd271535c
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2164-5515&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2164-5515&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2164-5515&client=summon